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Abstract 
Proteins and peptides have been increasingly used to treat many diseases 
including autoimmune diseases and cancer. The benefits of using peptides and 
proteins as drugs for treatment are higher target specificity and pharmacological 
potency when compared to traditional small molecule drugs. However, the 
instability and immunogenicity of peptides and proteins can limit their translation 
as therapeutics. Several strategies have been used to improve the physical and 
chemical stability of peptides and proteins or to extend the half-life in vivo such 
as modification of N- and C-terminus, PEGylation and cyclization. In addition, 
glycosylation is a post-traditional modification that can improve the stability of 
peptides and proteins. Current approaches for synthetic glycosylation often use 
multiple steps, such as chemical modification of the glycans to form reactive 
compounds, protection of reactive groups that give undesirable products, using 
glycosyltransferases to transfer saccharide moieties to peptides and installation 
of linker molecules to improve reaction efficiency. Two different peptides, 
aminooxy-proteolipid peptide (AoPLP), and proteolipid peptide (PLP, a known 
antigen in multiple sclerosis) have been used in this report. A single-step 
glycosylation in aqueous buffer was achieved by reacting an aminooxy peptide to 
N-acetyl glucosamine. A series of control experiments suggested that the product 
formed due to the reaction of the terminal aminooxy group on the peptide with 
the aldehyde group that is produced from the ring opening of NAG.
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1. Introduction 
Proteins and peptides have been increasingly used to treat many diseases 
including autoimmune diseases and cancer. Rituxan and Herceptin are two 
examples of antibodies that have been approved for the treatment of cancer. 
Parenteral administration is the most conventional route of delivery for protein 
drugs because of poor bioavailability by most other routes and greater control 
during clinical administration. Using peptides and proteins as drugs for treatment 
has advantages, such as higher target specificity and pharmacological potency 
when compared to traditional small molecule drugs (1). The instability and 
immunogenicity of peptides and proteins, however, can restrict their translation 
as therapeutics. Several methods have been used to improve the physical and 
chemical stability of peptides and proteins or to extend the half-life in vivo (1, 2, 
3). Glycosylation is a post-traditional modification that can improve the stability of 
peptides and proteins; however, glycosylation is typically heterogeneous and 
results from a complex reaction pathway. New methods to synthetically 
glycosylate peptides and proteins are needed. 
 
1.1 Methods to improve peptide and protein stabilities 
Due to the structural complexity of the peptide and protein when 
compared to traditional small molecule drugs, the structural instability issues of 
this class of molecules generally remains one of the biggest challenges to their 
pharmaceutical uses (1). Therefore, different strategies have been used to 
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improve peptide and protein stability. These strategies include external 
stabilization by affecting the properties of the surrounding solvent by adding 
stabilizing excipients such as amino acids, sugars, polyols, metals, serum 
albumin and phospholipids (1, 4, 5). Also, internal stabilization has been used to 
improve peptide and protein stability by altering the structural characteristics of 
the protein through chemical modifications such as modification of N- and C-
terminus, PEGylation, replacement of amino acids that are susceptible to 
degradation, cyclization and glycosylation (1, 4, 5).  
Several proteolytic enzymes, exopeptidases, occurring in plasma, liver 
and kidney can remove of an amino acid from the end of a peptide chain. These 
enzymes are classified into two categories: (1) aminopeptidase where the 
cleavage of a single amino acid occurs from the amino terminal and (2) 
carboxypeptidase where the cleavage of a single amino acid occurs from the 
carboxylic end. A modification of either or both of the peptide and protein drug 
termini can in many cases increase enzymatic stability (2). One common 
example for terminal modification is N-acetylation and C-amidation. For example, 
it was found that C-terminal amidation and N-terminal acetylation of the 
immunogenic peptide MART-I27–35 prolonged the have life of the peptide by 
inhibiting proteolylic degradation (6).  
A replacement of amino acids that are susceptible to degradation is 
another strategy to delay degradation and improve peptide and protein stability. 
For example, it was found that the half-life of luteinizing hormone releasing 
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hormone (LHRH) was increase from 15 min to 3.5 hours when glycine at residue 
six was substituted with D-leucine (7).  
 PEGylation is also another to method improve peptide and protein stability. 
Polyethylene glycols (PEGs) are mostly attached to Lys amino groups and Cys 
thiol groups in proteins. PEGylation of proteins can exhibit increased stability, 
improved solubility, decreased immunogenicity, increased circulation half-lives, 
and lower toxicity (8). It is known that substances with a molecular mass below 5 
kDa that are not bound to plasma proteins are excreted via the renal route (1). 
Increasing the molecular mass of proteins can prolong the plasma half-life by 
inhibiting renal excretion. PEGylation can also inhibit the proteolytic degradation 
by masking the residues that are susceptible to degradation (9). For example, 
conjugation of PEG20000 to insulin increases the protein’s enzymatic stability in 
blood (10). PEGs are generally considered to be safe and to have very low 
toxicity. 
Moreover, cyclization of a peptide or protein is a method to inhibit 
proteolytic degradation and to prolong circulation half life time. For example, it 
was found that the half life of Growth regulating factor (GRF) was increase form 
13 minutes to 2 hours when side-chain to side-chain cyclization between Asp8 
and Lys12 amino acid residues was occurred (11).  
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1.2 Importance of glycosylation  
Glycoproteins and glycopeptides are widely used in biological research 
and in drug and vaccine discovery. Glycosylation of proteins plays a role in 
protein folding, and can increase the stability of some proteins by preventing 
chemical reactions and physical instabilities (1). Glycosylation of peptides can 
produce different effects on antibody binding to the peptides. Some 
oligosaccharide units can be antigenic themselves and produce various anti-
carbohydrate antibodies (12). However, there are also cases where antibodies 
recognize specific oligosaccharide structures and adjacent amino acid residues 
(13). In contrast to anti-carbohydrate antibodies, antibodies that recognize 
glycopeptidic epitopes directly do not react with free oligosaccharides. Another 
type of epitope occurs when antibodies recognize the epitope by its linear 
sequence of amino acids in a particular conformation. Glycosylation of protein is 
necessary for protecting the conformational structure that is required for antibody 
binding (13). The glycan moiety of a glycoprotein plays an important role in its 
pharmacokinetic properties. The structures can be involved in tissue targeting 
and can modulate biological activities (1). Some studies suggest that 
glycosylation of peptides can increase the specificity of the peptide epitope that 
binds to the antibody (14). Therefore, glycosylated peptides can be used in the 
design of vaccines. For example, it was found that increasing glycosylation of a 
synthetic 25-amino acid fragment of the MUCI core protein with N-
acetylgalactosamine (GalNAc) showed greater reactivity with C595 antibody (15). 
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Several amino acids are susceptible to chemical degradation, such as 
deamidation (glutamine and asparagine), oxidation (histidine, methionine, 
cysteine, tryptophan, and tyrosine), and disulfide fragmentation (cysteine). 
Peptide hydrolysis can be produced either by proteases or by pH sensitive 
backbone sequences, at Asp-Gly and Asp-Pro (1, 8). Several studies show that 
glycosylation can also improve proteolytic stability of peptides and proteins. This 
proteolytic stability results from steric hindrance that is provided by glycans such 
as NAG, galactose, and sialic acid (1, 16). Moreover, glycosylation can improve 
the stability of peptides and proteins by inhibiting oxidation.  Oxidation of 
peptides and proteins can occur in several amino acid side chains such histidine, 
methionine, cysteine, tryptophan, and tyrosine. When a protein formulation is 
exposed to ultraviolet light in the presence of oxygen, the protein can be oxidized 
and form undesirable products. For example, the deglycosylated form of 
erythropoietin was found to be more susceptible to oxidation than the naturally 
glycosylated erythropoietin (17). Chemical instability due to either disulfide or 
non-disulfide crosslinking can also be prevented by glycosylation. Formation of 
these covalently linked disulfide species in proteins can lead to loss of bioactivity 
and formation of insoluble protein aggregates. Several studies suggest that the 
presence of glycan at the protein surface provides intermolecular steric repulsion 
between the protein species prone to crosslinking (1).  
Glycosylation can also provide physical stability. It is known that 
hydrophobic residues are located inside the protein core to avoid exposing them 
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to aqueous solution, giving rise to a compact native state. Several types of 
interactions, such as electrostatic, charge-charge interactions, hydrogen bonds, 
and Van der Waals interactions stabilize the native state. The conformational 
stability of folded proteins is very sensitive to the environmental conditions such 
as temperature, pH, ionic strength, and the presence of chemical denaturants. 
Changing the temperature, pH, or ionic strength can lead to changes in protein 
conformation and can produce unfolded structures. It was found that 
glycosylation could increase the stability of proteins against changes in pH or 
temperature, and against the effects of chemical denaturants, such as urea and 
guadinidium hydrochloride (1). It was also found that glycosylation can improve 
the solubility of proteins by providing favorable interactions between the surface 
of the glycoprotein and the solvent molecules (1).  
 
1.3 Types of glycosylation 
Glycosylation takes place in the endoplasmic reticulum (ER) and golgi 
apparatus and is catalyzed by the combination of glycosyltransferases and 
glycosidases present in the cell (18, 19, 20). It was estimated that at least 50% of 
all mammalian proteins are glycosylated (21). Many protein residues have been 
found to be glycosylated by different glycans such as fucose, galactose, 
mannose (Man), NAG, N-acetylgalactosamine, and sialic acid (N-
acetylneuraminic acid) (22, 23). 
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 Glycosylation is classified by type based on the atom of the amino acid 
that binds to the glycan. In N-glycosylation, glycans attach to the side chain 
nitrogen of asparagine in the sequence containing Asn-Xxx-Ser/Thr, where Xxx 
corresponds to any amino acid except for proline (1, 24). In O-glycosylation, 
glycans attach to the side chain hydroxyl oxygen of serine, threonine or tyrosine. 
This type of glycosylation does not require a unique sequence such as in the 
case of N-linked glycans (1). There is also another rare type of glycosylation, 
which is called C-glycosylation, where a glycan can attach to a carbon on a 
tryptophan side-chain. The structure of protein-linked oligosaccharide chains 
depends on several factors involved in the biosynthetic machinery of the cell, 
such as the precence of glycosyltransferases and other enzymes, the availability 
of oligosaccharides and the presence of the protein or glycoprotein acceptor in 
the cell (24).  
 
1.4 Reaction of aminooxy compounds with NAG 
It is known that aminooxy groups are more reactive than primary amines. 
The reactivity of the aminooxy group could be due to the lower pKa of the 
aminooxy group (pKa = 5-6) as compared to an amino group (pKa ~9). This 
keeps the aminooxy group unprotonated at lower pH and makes it a better 
nucleophile. Our group found that there appeared to be a reaction between the 
aminooxy peptides and the N-acetyl amide group of NAG. Mass spectroscopy 
data indicated that there was a reaction product between NAG and O-
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(carboxymethyl) hydroxylamine (OCMH) (Figure 1). The H1 NMR data (Figure 2) 
and C13 NMR (Figure 3) confirmed that the reaction occurred. In the H1 NMR, 
product spectra showed the appearance of peaks at ~6.5 and 7.5 ppm 
corresponding to the change in the environment caused by the product. In C13 
NMR, the product spectra showed that the amide carbon peak (~175 ppm) 
shifted to ~150 ppm corresponding to the product formation. In addition, the 
aminooxy reactive peptide can be conjugated to hyaluronic acid (HA), which is a 
polymer chain containing NAG. Although the data suggested that a reaction 
occurred, the product formed and reaction kinetics have not been thoroughly 
studied and the reaction has not been characterized and optimized. 
Due to the importance of glycosylation on the physical and chemical 
stability of peptides and proteins, simple synthetic glycosylation approaches are 
needed. Aminooxy chemistry may provide a viable option as evidenced by our 
preliminary studies. Here, the reaction kinetics of adding NAG to two different 
peptides, aminooxy-proteolipid peptide (AoPLP), and proteolipid peptide (PLP, a 
known antigen in multiple sclerosis) with an amine terminus was studied, and the 
reactivity of these peptides was compared. The reaction conditions were 
examined at various pH and buffer.  
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2. Materials and Methods 
2.2 Materials 
N-acetyl glucosamine, 3-O-Methyl-N-acetyl-D-glucosamine, benzyl-2-
acetamido-2-deoxy-α-D-galactopyranoside, acetanilide, O-allyl-hydroxylamine,  
O-Benzyl-hydroxylamine, O-(carboxymethyl) hydroxylamine hemihydrochloride 
(OCMH), O-methylhydroxylamine and Anthranilic acid were purchased from  
Sigma. Amino acids were purchased from Peptides International. Analytical 
grade acetonitrile, sodium cyanoborohydride, research grade sodium acetate, 
acetic acid, citric acid, sodium citrate monosodium phosphate, disodium 
phosphate colchicine and synthesis grade trifluoro acetic acid (TFA) were 
purchased from Fisher Scientific. Peptides were synthesized in house. Water 
was offered by a Labconco Water PRO PS ultrapure water purification unit.  
 
2.2 Methods 
2.2.1 Peptide synthesis 
Peptides were synthesized using 9-fluorenylmethyloxy-carbonyl-protected 
amino acid chemistry on polyethylene glycol-polystyrene resins. The peptides 
synthesized were aminooxy-proteolipid peptide (AoPLP) and proteolipid peptide 
(PLP) (Figure 4), which is known to be an antigen epitope in multiple sclerosis. 
Peptides were cleaved from the resin, and the crude peptides were isolated by 
precipitation in ether. Peptides were purified by high performance liquid 
chromatography (HPLC) using a C18 column. Analytical HPLC and mass 
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spectroscopy (MS) were used to calculate purity and confirm the identity of the 
synthesized peptides. 
 
2.2.2 Reaction of peptides (AoPLP and PLP) with NAG and other 
compounds 
 Three milligrams of each peptide (1.9 mM of AoPLP and 2 mM of PLP) 
were mixed with 1.7 mg of NAG (8 mM) in 1 mL of acetate buffer (50 mM), pH 5. 
After addition of all reactive species the pH was measured and adjusted to 5. The 
reactions were run for 17 hours at room temperature. For AoPLP and PLP, three 
different pH values have been used: pH 5 acetate buffer (50 mM), pH 6 citrate 
buffer (50 mM), and pH 7 phosphate buffer (50 mM). Moreover, four different 
amide compounds, benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside, 
colchicine, acetanilide and 3-O-methyl-N-acetyl-D-glucosamine (Figure 5) have 
been used to examine the potential reactivity of aminooxy peptide (AoPLP) with 
amide groups. For colchicine and 3-O-Methyl-N-acetyl-D-glucosamine, the 
reaction conditions were similar to those of the previous reaction. However, 
benzyl-2-acetamido-2-deoxy-α-D-galacto-pyranoside and acetanilide are only 
partially soluble in water. Therefore, acetonitrile-acetate buffer (40:60) was used 
to increase the solubility. After addition of all reactive species the pH was 
measured and adjusted to 5. The reactions were run for 17 hours at room 
temperature. 
 
 
 13 
2.2.3 Investigation the reacting site 
This experiment has been carried out to examine the site of reaction of 
aminooxy groups. Different aminooxy compounds, (O-allyl-hydroxylamine, O-
benzyl-hydroxylamine, O-(carboxymethyl) hydroxylamine hemihydrochloride 
(OCMH) and O-methylhydroxylamine) solutions have been prepared with 
concentration of 0.25 M in distilled water. 34.25 mg of Anthranilic acid (0.25 M) 
and 31.42 of sodium cyanoborohydride (0.5 M) were dissolved in 1ml of 4% (w/v) 
sodium acetate trihydrate and 2% (w/v) of boric acid in methanol (mixture I). 
Also, 31.42 mg of sodium cyanoborohydride was dissolved in 1ml of 4% (w/v) 
sodium acetate trihydrate and 2% (w/v) of boric acid in methanol (mixture II). 
55.3 mg of NAG (0.25 M) was dissolved in 1 ml of distilled water. 40 μL of NAG 
solution was mixed with 40 μL of mixture I in four different tubes and 2 μL of 
acetic acid was added in each tube. The reaction was carried out at 80 0C for 
one hour. After that the reaction mixture was cooled at room temperature for one 
hour. 40 μL of each aminooxy solution was added to each tube. The reactions 
were carried out at room temperature for 17 hour followed by lyophilization. 
Electrospray ionization mass spectrometry was used to confirm the presence of 
any products. In other four different tubes, 40 μL of NAG solution was mixed with 
40 μL of mixture II. 40 μL of each aminooxy solution was added to each tube and 
2 μL of acetic acid was added in each tube. The reaction was carried out at 80 0C 
for one hour. Electrospray ionization mass spectrometry was used to confirm the 
presence of the product. 
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2.2.4 Mass Spectroscopy 
Electrospray ionization mass spectroscopy was used to determine the 
masses of synthesized peptides and the masses of conjugated peptides using a 
waters LCT premier ESI mass spectrometer running MassLynx software. 
Matrix assisted laser desorption/ionization (MALDI)-TOF was also used to 
determine the masses of conjugated peptides. MALDI-TOF MS spectra were 
acquired using a Voyager DE-STR mass spectrometer equipped with delayed 
extraction. An acceleration voltage of 20 kV and a nitrogen laser at 337 nm was 
used. Mass spectra were acquired in positive reflector mode. External calibration 
was used. Cyano-4-hydroxycinnamic acid was used as matrix.  
  
2.2.5 High Performance Liquid Chromatography 
   Peptide was quantified by gradient reversed phase HPLC (SHIMADZU) 
using a Vydac HPLC protein and peptide C18 column. The HPLC is composed of 
a SCL-20A SHIMADZU system controller, LC-10AT VP SHIMADZU liquid 
chromatograph, SIL-10A XL SHIMADZU auto-injector set at 75 μL injection 
volume, DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A 
SHIMADZU UV-vis detector (220 nm). The HPLC-UV system was controlled by a 
personal computer equipped with SHIMADZU class VP Software. Gradient 
elution was carried out at constant flow of 1 mL/min, from 100% A to 35% A 
(corresponding to 0% B to 65% B) for 50 min, followed by an isocratic elution at 
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75% B for 3 min. Mobile phase (A) was acetonitrile-water (5:95) with 0.1% TFA 
and mobile phase (B) was acetonitrile with 0.1% TFA. 
 
2.2.6 Size Exclusion Chromatography 
Size exclusion chromatography was used to isolate the product using 
Superdex Peptide 10/300 GL column, eluted isocratically. Three different mobile 
phases, (1) 0.1 M ammonium acetate at flow rate of 0.5 ml/min, (2) acetonitrile-
water (10:90) with 0.1% T trifluoroacetic acid (TFA) at flow rate of 0.5 ml/min, 
and (3) 0.1 M sodium phosphate at flow rate of 0.4 ml/min have been tried. The 
HPLC consisted of a SCL-20A SHIMADZU system controller, LC-10AT VP 
SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU auto-injector set at 
200 μL injection volume, DGU-14A SHIMADZU degasser, sample cooler, and 
SPD-10A SHIMADZU UV-vis detector (220 nm). The HPLC-UV system was 
controlled by a personal computer equipped with SHIMADZU class VP Software. 
 
3. Results and discussion  
3.1 Peptide synthesis 
After the synthesized peptides were purified by high performance liquid 
chromatography (HPLC) using a C18 column, the identity of the synthesized 
peptides was confirmed by electrospray ionization mass spectroscopy. The 
molecular weights for AoPLP and PLP were 1593.81 and 1520.7, respectively 
(Figure 6 and 7). The purity of the synthesized peptides was calculated by 
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gradient reversed phase HPLC using a Vydac HPLC protein and peptide C18 
column. The purities of AoPLP and PLP were 89% and 97% respectively (Figure 
8 and 9).  
 
3.2 Reaction of the peptides (AoPLP and PLP) with NAG 
 The reaction of PLP (Mw 1521.76) with NAG (Mw 221) was carried out at 
pH 5 in acetate buffer (50mM) for 17 hours.  The expected molecular weight of 
the product of the reaction of amino terminus group with reducing end of NAG is 
1724. The product was analyzed by mass spectroscopy. The spectrum for the 
reaction product between PLP and NAG showed the absence of the product (Mw 
1724) at pH 5 (Figure 10) 
  The reaction of AoPLP (Mw 1594.8) with NAG (Mw 221) has been carried 
out under similar conditions. The spectrum for the reaction product between 
AoPLP and NAG (Figure 11) showed the presence of the product (Mw 1798). 
The product was also detected after reacting at pH 6 (Figure 12) and 7 (Figure 
13). The reactivity of the aminooxy group can be due to the lower pKa of the 
aminooxy group (pKa = 5-6) as compared to amino group (pKa ~9). This keeps 
the aminooxy group unprotonated at lower pH and makes it a better nucleophile. 
The formed product could be due to the reaction of the aminooxy group on the 
peptide with the amide group on NAG or with the aldehyde group that is 
produced from the ring opening of NAG. Therefore, different amide compounds 
have been used to examine the reactivity of aminooxy group with amide group. 
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The reaction between AoPLP and NAG was also carried out at pH 6 in citrate 
buffer (50 mM) and pH 7 in phosphate buffer (50 mM).  
 The reaction has been carried out in aqueous buffer, thus avoiding harsh 
catalysts or reaction conditions. In addition, the aminooxy group is significantly 
more reactive than primary amines, thus conferring the desired specificity for 
glycosylation of peptides (25, 26). Simplified reaction schemes would be a 
benefit for synthetic glycosylation. Due to stability concerns, peptides and 
proteins cannot be exposed to many of the conditions that are required for 
glycosylation such as organic solvent, high or low pH, and temperature (27). In 
current approaches, multiple steps are often used for synthetic glycosylation, 
such as chemical modification of the glycans to form reactive compounds, 
protection of reactive groups that give undesirable products, using 
glycosyltransferases to transfer saccharide moieties to peptides and installation 
of linker molecules to improve reaction efficiency (28, 29,30). Some of these 
steps need to be carried out at harsh conditions that may be harmful for the 
synthesis of glycoproteins, and consequently, often afford fairly poor yields. 
 For example, Thomas J. Styslinger’s group has developed a strategy for 
glycosylation of hemoglobin with variable molecular weight oligosaccharides. 
This strategy involves three steps for glycosylation of hemoglobin. In the first 
step, an aminooxy group on polyethylene glycol (PEG) was reacted with the 
aldehyde available in the open-chain conformation of the reducing end 
carbohydrate. The second step involved installation of a reactive terminal 
 
 18 
functional group on PEG. In the third step, thiol-targeting chemistry was used to 
successfully conjugate glycans to a cysteine residue on the hemoglobin (29). 
These inconveniences and lengthy processes make many of the current 
glycosylation methods overly complicated for therapeutic glycoproteins and 
unrealistic for scale-up (28, 31). In this thesis, a single-step glycosylation in 
aqueous buffer was achieved by reacting an aminooxy peptide directly to N-
acetyl glucosamine. 
 
3.3 Size exclusion chromatography 
Size exclusion chromatography was used to isolate the product. Different 
mobile phases were tested: 0.1 mM ammonium acetate at flow rate 0.5 ml/min 
and volume of injection of 200 μL, acetonitrile-water (10:90) with 0.1% 
trifluoroacetic acid (TFA) at flow rate 0.5 ml/min and volume of injection of 200 
μL, and 0.1 mM sodium phosphate at flow rate 0.4 ml/min and volume of injection 
of 100 μL. When ammonium acetate (Figure 14) and acetonitrile-water (Figure 
15) were used as mobile phases, the separation of the peaks was sufficient to 
isolate the product. The separation of the peaks was better when using sodium 
phosphate as mobile phase (Figure 16). Each of the three peaks was identified 
by injecting free peptide (AoPLP) and free NAG. The first peak was the product 
(retention time = 37 min), the second peak was AoPLP (retention time = 39.8 
min), and the third peak was NAG (retention time = 42.7 min).  
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3.4 Examine the reactivity of amide group 
 There are two proposed pathways for forming the product. The product 
formed could be due to the reaction of the terminal aminooxy group on the 
peptide with the amide group on NAG or with the aldehyde group that is 
produced from the ring opening of NAG. Therefore, four different amide 
compounds, benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside (Mw 311.3), 
colchicine (MW 399.4) acetanilide (MW 135.16) and 3-O-methyl-N-acetyl-D-
glucosamine (MW 235.23) were used to probe the reactivity of the aminooxy 
group (AoPLP) with the carbonyl of the amide group. For colchicine, and 3-O-
methyl-N-acetyl-D-glucosamine, the reaction conditions were similar to those of 
the previous reaction. However, benzyl-2-acetamido-2-deoxy-α-D-galacto-
pyranoside and acetanilide were only partially soluble in water. Therefore, 
acetonitrile-acetate buffer (40:60) was used to increase the solubility.  
For the reaction of AoPLP with benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside (expected product mass is 1886.8) (Figure 17) with colchicine 
(expected product mass is 1975) (Figure 18), with acetanilide (expected product 
mass is 1710.9) (Figure 19) and with 3-O-methyl-N-acetyl-D-glucosamine 
(expected product Mw 1810.9) (Figure 20) the mass spectrum for the reaction 
products showed the absence of the products. The mass spectrum data 
indicated that there was no reaction between AoPLP and the four amide 
compounds. The mass spectrum data may suggest that the product that is 
formed from the reaction of AoPLP with NAG is due to the ring opening of NAG. 
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There are some studies suggested that the product that is formed is due to the 
ring opening of NAG. For example, conjugation of florescent probes that  have an 
amino group such as 2-aminobenzamide and anthranilic acid with protein-
drivative glycans (32). Due to the low intrinsic spectral activity and detection of 
glycan during chromatographic processes, this fluorescent labeling technique 
was used. 
 
3.5 Investigation of the NAG aldehyde reaction site 
  In this experiment, the aldehyde group that is formed from the ring of NAG 
was blocked by reacting it with the amino group of anthranilic acid. Sodium 
cyanoborohydride was added to reduce the imine group forming secondary 
amine and making the reaction irreversible. Therefore, the reaction will be 
pushed toward the product. The expected mass for the product that results from 
the reaction of NAG wih anthranilic acid after reducing the imine bond is 342.1. 
After that, different aminooxy compounds O-allyl-hydroxylamine, O-benzyl-
hydroxylamine, O-(carboxymethyl) hydroxylamine hemihydrochloride (OCMH), 
and O-methylhydroxylamine were added to investigate the reactivity of amide  
group (Scheme 1). The expected masses for products that would result from the 
reaction of amide group of the blocked NAG with the aminooxy group of O-
methylhydroxylamine, O-allyl-hydroxylamine, O-Benzyl-hydroxylamine, and or O-
(carboxymethyl) hydroxylamine hemihydrochloride (OCMH) are 371.2, 397.2, 
447.2, and 415.2, respectively. The mass spectrum data indicated that there was 
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a reaction between NAG and anthranilic acid. However, the mass spectrum data 
indicated that there were no reactions between the blocked NAG and the 
aminooxy compounds (Figure 21, 22, 23 and 24).  
In another experiment, the reactions between NAG and aminooxy 
compounds were carried out in the presence of a reducing agent (sodium 
cyanoborohydride). The expected masses for the products that resulted from the 
reaction of NAG with the aminooxy group of O-methylhydroxylamine, O-allyl-
hydroxylamine, O-benzyl-hydroxylamine, and O-(carboxymethyl) hydroxylamine 
hemihydrochloride (OCMH) without reducing the oxime group are 250.13, 
276.13, 326.15 and 294.1063 and after reducing reducing the oxime bond are 
252.14,  397.14, 328.16 and  294.12, respectively. The mass spectrum data 
indicated that there were reactions between the NAG and the aminooxy 
compounds (Figure 25, 26, 27 and 28). Both of experiments suggest that the 
product that was formed from the reaction of AoPLP with NAG was due to the 
ring opening of NAG. After blocking the aldehyde group that was produced from 
the ring opening of NAG, the reactions of aminooxy compounds with NAG were 
prevented. Fourier Transform Infrared Spectroscopy (FTIR) can also be used to 
investigate the reaction site by looking at the change on the amide bonding 
environments at 1650 and 1550 cm-1 throughout the course of the reaction of 
aminooxy compound and NAG (33). 
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4. Conclusion 
 In this study, two different peptides, AoPLP and PLP, were used to probe 
the reactivity with NAG. It was found that there was no reaction between PLP 
and NAG at pH 5. However, the reaction between AoPLP and NAG was 
observed at pH 5, 6 and 7.  Two different experiments were used to investigate 
the reacting site (peptide with the amide group on NAG or with the aldehyde 
group that is produced from the ring opening of NAG) of the aminooxy peptide 
(AoPLP). In the first experiment, AoPLP was reacted with four different amide 
compounds. The mass spectra data indicated that there was no reaction 
between the aminooxy peptide and the amide compounds. In the second 
experiment, the aldehyde group that is produced from the ring opening of NAG 
was blocked by reacting it with anthranilic acid. After that, the blocked NAG was 
reacted with different aminooxy compounds. The mass spectra data indicated 
that there was no reaction between the aminooxy compounds and the blocked 
NAG. However, when the aminooxy was reacted with free NAG, the product that 
resulted from the reaction of aminoxy group with the aldehyde group was 
observed. These experiments also suggested that the product that was formed 
from the reaction of AoPLP with NAG was due to the ring opening of NAG. In this 
report, a single-step glycosylation was achieved by reacting an aminooxy peptide 
to N-acetyl glucosamine.  
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Scheme 1: Proposed reaction scheme for the NAG aldehyde reaction site.        
1. NAG. 2. Anthranilic acid. 3. Labeled NAG without reducing the oxime bond.   
4. Labeled NAG after reducing the oxime bond. 5. Aminooxy compounds.          
6. A possible NAG reaction productat the amide carbonyl carbon.   
 
 
Scheme2: Proposed reaction scheme for the reaction of NAG and OCMH.  
7. OCMH. 8. A possible amide reaction product. 
 
1 2 3 4 
5 6 
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Figure 1: ESI+ Mass spectroscopy of the unpurified reaction product between 
NAG and OCMH showing the product peak at 295 and product plus Na+ at 317 
(Joshua Sestak’s thesis). 
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Figure 2: H1 NMR spectrum of (A) NAG, and (B) OCMH, (C) reaction product of 
NAG monomer with OCMH (Joshua Sestak’s thesis).  
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Figure 3: C13 NMR spectrum of (A) NAG monomer, (B) OCMH, (C) reaction 
product of NAG monomer and OCMH (Joshua Sestak’s thesis). 
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(a) 
(b) 
Figure 4: The structures of (a) PLP and (b) AoPLP. 
 
 
                        
        (a)                                                               (b)                                                           
                                     
  (c)                                                                     (d) 
Figure 5: The structures of (a) colchicine, (b) Benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside, (c) acetanilide, (d) 3-O-Methyl-N-acetyl-D-glucosamine. 
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Figure 6: ESI+ mass spectroscopy of synthesized AoPLP peptide showing the 
peaks at 532.3 (AoPLP peptide (+3)) and at 797.9 (AoPLP peptide (+2)). 
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Figure 7: ESI+ mass spectroscopy of synthesized PLP peptide showing the 
peaks at 507.9 (PLP peptide (+3)) and at 761.4 (PLP peptide (+2)). 
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Figure 8: Reversed phase HPLC chromatogram of AoPLP peptide shows the 
purity of AoPLP peptide (89%). 
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Figure 9: Reversed phase HPLC chromatogram of PLP shows the purity of 
AoPLP peptide (97%). 
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Figure 10: ESI+ mass spectroscopy of the mixture of PLP and NAG showing the 
absence of any product peak at pH 5, acetate buffer. 
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Figure 11: ESI+ mass spectroscopy of the mixture of PLP and NAG showing the 
presence of the product peak at pH 5, acetate buffer. 
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Figure 12: MALDI mass spectroscopy of the mixture of AoPLP and NAG 
showing the presence of the product peak at pH 6, citrate buffer. 
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Figure 13: MALDI mass spectroscopy of the mixture of AoPLP and NAG 
showing the presence of the product peak at pH 7, phosphate buffer. 
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Figure 14: Size exclusion chromatogram for the mixture of AoPLP and NAG 
showing poorly separated peaks when 0.1 mM ammonium acetate was used as 
the mobile phase. 
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Figure 15: Size exclusion chromatogram for the mixture of AoPLP and NAG 
showing poorly separated peaks when acetonitrile-water (10:90) with 0.1% 
trifluoroacetic acid was used as the mobile phase. 
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Figure 16: Size exclusion chromatograms for NAG only, AoPLP only and the 
product of AoPLP and NAG when 0.1 mM sodium phosphate was used as the 
mobile phase. 
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Figure 17: MALDI mass spectroscopy of the mixture of AoPLP and benzyl-2-
acetamido-2-deoxy-α-D-galactopyranoside showing the absence of the product 
peak (expected product mass 1886.8). 
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Figure 18: MALDI mass spectroscopy of the mixture of AoPLP and colchicine 
showing the absence of the product peak (expected product mass 1975). 
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Figure 19: MALDI mass spectroscopy of the mixture of AoPLP and Acetanilide 
showing the the absence of the product peak (expected product mass 1711.92) 
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Figure 20: MALDI mass spectroscopy of the mixture of AoPLP and 3-O-methyl-
N-acetyl-D-glucosamine showing the absence of the product peak (expected 
product mass 1810.9). 
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Figure 21: ESI- mass spectroscopy of the mixture of O-methylhydroxylamine 
and blocked NAG showing the absence of the product peak (expected product 
mass 371.2). 
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Figure 22: ESI- mass spectroscopy of the mixture of O-allyl-hydroxylamine and 
blocked NAG showing the absence of the product peak (expected product mass 
397.2). 
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Figure 23: ESI- mass spectroscopy of the mixture of O-benzylhydroxylamine and  
blocked NAG showing the absence of the product peak (expected product Mw 
447.2006). 
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Figure 24: ESI- mass spectroscopy of the mixture O-(carboxymethyl) 
hydroxylamine and blocked NAG showing the absence of the product peak 
(expected product mass 415.2). 
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Figure 25: ESI+ mass spectroscopy of the mixture of O-methylhydroxylamine 
and unblocked NAG showing the presence of the product peak. 
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Figure 26: ESI+ mass spectroscopy of the mixture of O-allyl-hydroxylamine and 
unblocked NAG showing the presence of the product peak. 
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Figure 27: ESI+ mass spectroscopy of the mixture of O-benzylhydroxylamine  
and unblocked NAG showing the presence of the product peak 
 
 
 
 M R 
Mass=221.09 Mass= 123.0684 
Mass= 326.1478 
Mass=328.1634 
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Figure 28: ESI+ mass spectroscopy of the mixture O-(carboxymethyl) 
hydroxylamine and unblocked NAG showing the presence of the product peak. 
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